1. Anorectic and aversive effects of GLP-1 receptor agonism are mediated by brainstem cholecystokinin neurons, and modulated by GIP receptor activation.
- Author
-
Costa A, Ai M, Nunn N, Culotta I, Hunter J, Boudjadja MB, Valencia-Torres L, Aviello G, Hodson DJ, Snider BM, Coskun T, Emmerson PJ, Luckman SM, and D'Agostino G
- Subjects
- Animals, Appetite drug effects, Appetite Depressants pharmacology, Blood Glucose drug effects, Exenatide pharmacology, Female, Glucagon metabolism, Glucagon-Like Peptide 1 pharmacology, Glucagon-Like Peptide-1 Receptor agonists, Glucagon-Like Peptide-1 Receptor physiology, Hypoglycemic Agents pharmacology, Insulin pharmacology, Liraglutide pharmacology, Male, Mice, Mice, Inbred C57BL, Neurons metabolism, Receptors, Gastrointestinal Hormone metabolism, Cholecystokinin pharmacology, Gastric Inhibitory Polypeptide metabolism, Glucagon-Like Peptide-1 Receptor metabolism
- Abstract
Objective: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are effective medications to reduce appetite and body weight. These actions are centrally mediated; however, the neuronal substrates involved are poorly understood., Methods: We employed a combination of neuroanatomical, genetic, and behavioral approaches in the mouse to investigate the involvement of caudal brainstem cholecystokinin-expressing neurons in the effect of the GLP-1RA exendin-4. We further confirmed key neuroanatomical findings in the non-human primate brain., Results: We found that cholecystokinin-expressing neurons in the caudal brainstem are required for the anorectic and body weight-lowering effects of GLP-1RAs and for the induction of GLP-1RA-induced conditioned taste avoidance. We further show that, while cholecystokinin-expressing neurons are not a direct target for glucose-dependent insulinotropic peptide (GIP), GIP receptor activation results in a reduced recruitment of these GLP-1RA-responsive neurons and a selective reduction of conditioned taste avoidance., Conclusions: In addition to disclosing a neuronal population required for the full appetite- and body weight-lowering effect of GLP-1RAs, our data also provide a novel framework for understanding and ameliorating GLP-1RA-induced nausea - a major factor for withdrawal from treatment., (Copyright © 2021 The Authors. Published by Elsevier GmbH.. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF